Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The severity of atopic dermatitis according to the EASI index (Eczema Area and Severity Index, index of prevalence and severity of eczema)\> 7 points (moderate and / or severe course of atopic dermatitis);~2. A burdened family allergic history (at least one of the parents has atopic dermatitis, food allergy, bronchial asthma and / or allergic rhinitis);~3. The presence of sensitization in the child to one or more of the studied food and household allergens, determined at the screening stage by the ImmunoCAP method: cow's milk protein, chicken egg protein, wheat, soy, hx2 house dust mixture: Dermatophagoides pteronyssinus, D. farinae, Blatella germanica .~Exclusion Criteria:~1. Use of topical calcineurin inhibitors (pimecrolimus) in the last 30 days prior to inclusion in the study;~2. A history of concomitant severe neurological, endocrinological, cardiovascular, hepatic and renal diseases;~3. The presence of acute bacterial, viral infections;~4. The child's lack of sensitization to detectable food and household allergens;~5. Clinically significant changes in the general analysis of urine, general analysis of blood, biochemical analysis of blood;~6. Refusal to sign an informed consent to participate in the study;~7. Inability to observe the patient during the study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Experimental group №1 (Type: EXPERIMENTAL): proactive therapy with local calcineurin inhibitors + emollients
- Experimental group №2 (Type: ACTIVE_COMPARATOR): proactive therapy with local glucocorticosteroids + emollients

Based on this trial design, predict the completion outcome and termination type (if applicable).